These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8877019)

  • 1. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Jallad NS; Wilhelm JA; Bikhazi GB
    Br J Clin Pharmacol; 1996 Sep; 42(3):301-6. PubMed ID: 8877019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.
    Matzke GR; Frye RF; Alexander AC; Reynolds R; Dixon R; Johnston J; Rault RM
    J Clin Pharmacol; 1996 Feb; 36(2):144-51. PubMed ID: 8852390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
    Liao RF; Zeng ZP; Wen YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1816-9. PubMed ID: 18971181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
    Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J
    Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study.
    Rosen DA; Morris JL; Rosen KR; Nelson ER; Steelman RJ; Gustafson RA; Wilhelm JA; Chang CT; Thackara JW; Frye RF
    Pharmacotherapy; 2000 Jul; 20(7):745-9. PubMed ID: 10907964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of the opioid antagonist, nalmefene, in rat and dog.
    Murthy SS; Mathur C; Kvalo LT; Lessor RA; Wilhelm JA
    Xenobiotica; 1996 Jul; 26(7):779-92. PubMed ID: 8819305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nalmefene: intravenous safety and kinetics of a new opioid antagonist.
    Dixon R; Howes J; Gentile J; Hsu HB; Hsiao J; Garg D; Weidler D; Meyer M; Tuttle R
    Clin Pharmacol Ther; 1986 Jan; 39(1):49-53. PubMed ID: 3943269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
    Gaekens T; Guillaume M; Borghys H; De Zwart LL; de Vries R; Embrechts RC; Vermeulen A; Megens AA; Leysen JE; Herdewijn P; Annaert PP; Atack JR
    J Control Release; 2016 Jun; 232():196-202. PubMed ID: 27107723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
    Turncliff R; DiPetrillo L; Silverman B; Ehrich E
    Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans.
    Li P; Chen X; Dai X; Wen A; Zhang Y; Zhong D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):479-84. PubMed ID: 17329173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
    Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
    Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.
    Dixon R; Gentile J; Hsu HB; Hsiao J; Howes J; Garg D; Weidler D
    J Clin Pharmacol; 1987 Mar; 27(3):233-9. PubMed ID: 3680580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
    Krieter P; Gyaw S; Crystal R; Skolnick P
    J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC; Kleppner SR; McDonough J; Azar MR; Patel R
    Int J Pharm; 2004 Sep; 283(1-2):35-44. PubMed ID: 15363499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.